DB
HSTO

Dmitry Balyasny’s Histogen Inc. Common Stock HSTO Stock Holding History

Dmitry Balyasny’s Portfolio HSTO Stock Details HSTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-149
Closed -$137K – 2439
2017
Q4 		$137K Buy
+149
New +$138K ﹤0.01% 1956

Other funds holding HSTO

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return

Dmitry Balyasny's HSTO Position: Q1 2018 in Review

Dmitry Balyasny sold out of Histogen Inc. Common Stock (HSTO) in Q1 2018, closing a stake of 149 shares — an estimated $137K sold.

Dmitry Balyasny first reported a position in HSTO in Q4 2017 and held it in 1 quarter. The position peaked at $137K in Q4 2017. 73 funds tracked by Wall St. Rank hold HSTO as of Q1 2018.

  • Dmitry Balyasny reported no remaining Histogen Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Dmitry Balyasny sold 149 Histogen Inc. Common Stock shares in Q1 2018, an estimated $137K.
  • Dmitry Balyasny first reported a position in Histogen Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Dmitry Balyasny's Histogen Inc. Common Stock position peaked at $137K in Q4 2017.
  • 73 funds tracked by Wall St. Rank held Histogen Inc. Common Stock as of Q1 2018.

Based on Balyasny Asset Management's 13F filing for Q1 2018, filed 15 May 2018.